Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-01-23
2007-01-23
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S122000, C544S323000, C544S324000, C514S252140, C514S275000
Reexamination Certificate
active
11007923
ABSTRACT:
The present invention relates to trisubstituted pyrimidines of formulawhereinRato Reare defined as in claim 1, which are suitable for the treatment of illnesses in which β-amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
REFERENCES:
patent: 5147876 (1992-09-01), Mizuchi et al.
patent: 5703129 (1997-12-01), Felsenstein et al.
patent: 6197779 (2001-03-01), Andries et al.
patent: 6200977 (2001-03-01), Cushing et al.
patent: 6235746 (2001-05-01), Davis et al.
patent: 6245884 (2001-06-01), Hook
patent: 6448229 (2002-09-01), Teall
patent: 6683091 (2004-01-01), Asberom et al.
patent: 6713248 (2004-03-01), Roberts et al.
patent: 6753410 (2004-06-01), Nadin et al.
patent: 6756511 (2004-06-01), Castro Pineiro et al.
patent: 6800477 (2004-10-01), Patel et al.
patent: 6890956 (2005-05-01), Churcher et al.
patent: 2002/0183335 (2002-12-01), Hewawasam et al.
patent: 2003/0032647 (2003-02-01), Yamada et al.
patent: 2004/0102630 (2004-05-01), Brumby
patent: 2004/0224966 (2004-11-01), Brumby
patent: 40 29 650 (1992-03-01), None
patent: 0 379 806 (1990-08-01), None
patent: 0 945 443 (1999-09-01), None
patent: 1 223 170 (2002-07-01), None
patent: 1 277 741 (2003-01-01), None
patent: 3-127790 (1991-05-01), None
patent: WO 91/18887 (1991-12-01), None
patent: WO 97/19065 (1997-05-01), None
patent: WO 99/41253 (1999-08-01), None
patent: WO 99/50250 (1999-10-01), None
patent: WO 00/12485 (2000-03-01), None
patent: WO 00/12486 (2000-03-01), None
patent: WO 00/27825 (2000-05-01), None
patent: WO 00/27826 (2000-05-01), None
patent: WO 00/39101 (2000-07-01), None
patent: WO 00/53595 (2000-09-01), None
patent: WO 01/19825 (2001-03-01), None
patent: WO 200119825 (2001-03-01), None
patent: WO 01/55148 (2001-08-01), None
patent: WO 01/64653 (2001-09-01), None
patent: WO 01/64654 (2001-09-01), None
patent: WO 01/64655 (2001-09-01), None
patent: WO 01/64656 (2001-09-01), None
patent: WO 02/04429 (2002-01-01), None
patent: WO 02/066036 (2002-08-01), None
patent: WO 02/096888 (2002-12-01), None
Jill Murrell, et al. “A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease” Science, vol. 25, pp. 97-99, 1991.
Barbara Cordell “B-Amyloid Formation as a Potential Therapeutic Target for Alzheimer's Disease” Annual Review Pharmacology and Toxicology, 1994, 34:69-89.
Marie-Christine Chartier-Harlin, et al. “Early-onset Alzheimer's Disease caused by Mutations at Codon 717 of the B-amyloid Precursor Protein Gene” Nature, vol. 353, pp. 844-846, (1991).
Martin Citron, et al. “Mutation of the B-amyloid Precursor Protein in Familial Alzheimer's Disease Increases B-protein Production” Nature, vol. 360, pp. 672-674, 1992.
George G. Glenner, et al. “Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein” Biochem. Biophys. Res. Comm., vol. 120, No. 3, pp. 885-890, 1984.
K. Johnson-Wood, et al. “Amyloid precursor protein processing and AB42 deposition in a transgenic mouse model of Alzheimer disease” Proc.Natl.Acad.Sci.USA, vol. 94, pp. 1550-1555, 1997.
Dennis, J. Selkoe “Amyloid Protein and Alzheimer's Disease” Scientific American, Nov. 1991, pp. 68-78.
Bornemann, K. et al; “Trisubstituted Pyrimidines”; U.S. Appl. No. 10/272,160, filed Oct. 16, 2002.
Dahmann, G. et al; “Pyrimidine Derivatives”; U.S. Appl. No. 10/271,763, filed Oct. 16, 2002.
Dahmann, G. et al; Chemical Abstracts, vol. 138:321292, 2003.
Denny et al., Chemical Abstracts, vol. 134:237498, 2001.
EP Patent Abstracts of Japan; Publication No. 01327790; Patent No. JP 3-127790.
Boschelli, et al; “Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines: Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors”; J Med Chem 1998, 41, pp. 4365-4377.
Chemical Abstract: CA 117:48596 for DE 4029650 A1.
Selkoe, D. J., Science, vol. 275 (1997), pp. 630-631.
Selkoe, D. J., Nature, 399 (1999), A23-A31.
Esler, W. P. et al., Nature Cell Biology, 2 (2002), pp. 428-434.
Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, Iqbal, K. et al. (ed.), (2001), John Whiley & Sons Ltd., Ch. 72, pp. 777-788.
Bornemann Klaus
Briem Hans
Dorner-Ciossek Cornelia
Fechteler Katja
Fuchs Klaus
Boehringer Ingelheim Pharma GmbH & Co. KG
Datlow Philip I.
Devlin Mary Ellen
Habte Kahsay
Morris Michael P.
LandOfFree
Trisubstituted pyrimidines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Trisubstituted pyrimidines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Trisubstituted pyrimidines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3824308